Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LogicBio Therapeutics Inc. LOGC

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.


Recent & Breaking News (NDAQ:LOGC)

LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

PR Newswire 12 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, JVA, AKUS, LOGC

PR Newswire October 31, 2022

SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations

PR Newswire October 20, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAWW, LOGC, RFP, PBFX, RNWK

PR Newswire October 18, 2022

LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC

Business Wire October 18, 2022

SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations

PR Newswire October 14, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, LOGC, OIIM, JVA

PR Newswire October 11, 2022

LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC

Business Wire October 4, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, POSH, SSNT

PR Newswire October 4, 2022

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC

PR Newswire October 3, 2022

SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.

PR Newswire October 3, 2022

Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca

PR Newswire October 3, 2022

LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders

Business Wire October 3, 2022

Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

PR Newswire October 3, 2022

LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

PR Newswire September 21, 2022

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 15, 2022

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

PR Newswire May 17, 2022

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

PR Newswire May 16, 2022

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

PR Newswire May 11, 2022

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

PR Newswire May 9, 2022